Division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, USA.
Drug Resist Updat. 2010 Dec;13(6):172-9. doi: 10.1016/j.drup.2010.09.001. Epub 2010 Oct 13.
The goal of cancer therapy is to kill cancer cells. Many anticancer drugs are designed to kill cells by inducing apoptosis. However, the potency assays used for measuring the bioactivity of these products are generally cell viability assays which do not distinguish between cell death and growth inhibition. There are a number of commercial assays available to measure apoptosis; however, many of these assays are not appropriate for use in high-throughput screening formats preferred by industry to measure drug activity, also known as potency, due to their inherent low robustness and/or high variability. This review outlines the strengths and weaknesses of current apoptosis assays and highlights new promising assay developments for evaluation of anticancer therapeutics, such as the design of fluorescent and luminescent constructs to be applied as caspase substrates.
癌症治疗的目的是杀死癌细胞。许多抗癌药物旨在通过诱导细胞凋亡来杀死细胞。然而，用于测量这些产品生物活性的效力检测通常是细胞活力检测，它不能区分细胞死亡和生长抑制。有许多商业检测方法可用于测量细胞凋亡；然而，由于固有低稳健性和/或高变异性，许多这些检测方法不适用于工业中首选的用于测量药物活性（也称为效力）的高通量筛选格式。本综述概述了当前细胞凋亡检测方法的优缺点，并强调了新的有前途的检测方法的发展，用于评估抗癌治疗药物，例如设计荧光和发光构建体作为半胱天冬酶底物。
